Cingulate therapeutics filing

Author: ubxf

August undefined, 2024

WebOct 13, 2024 · Cingulate Therapeutics' IPO date and price. Cingulate is expected to start trading on Oct. 15. The company now plans to raise $40 million by offering 4.4 million … WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: Third Floor: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; Kansas City: …

Cingulate Therapeutics LLC - Company Profile and News

WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … WebCingulate Therapeutics is a Biotechnology, Pharmaceuticals, and Pharmaceutical Manufacturing company located in Morristown, New Jersey with $2.00 Million in revenue and 14 employees. Find top employees, contact details and business statistics at RocketReach. ... (28 currently) – along with the filing of multiple provisional applications ... first signs of liver failure

Cells Free Full-Text Developmental Changes of Human Neural ...

WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 6 SOUTH STREET: SUITE 203: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; MORRISTOWN: NEW … WebJul 3, 2024 · Cingulate Therapeutics - ‘D/A’ on 7/3/19 - Notice of an Exempt Offering of Securities - Seq. 1 - Amendment to Notice of an Exempt Offering of Securities -- primary_doc.xml/7.8 - Accession Number 0001593151-19-000001 - Filing - SEC WebFeb 8, 2024 · Cingulate Therapeutics LLC. February 8, 2024, ... (U.S.) and are instrumental for the filing of the New Drug Application to the U.S. Food and Drug Administration (FDA), expected in the second half ... campaignercrm software

SEC FORM D

Web8 rows · Jun 29, 2024 · Cingulate Therapeutics - Most recent fund raising on June 29, 2024 raised $7,000,000 in Equity and Debt WebCingulate General Information. Description. Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery … campaigner delivery ratingWebApr 6, 2024 · Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING stock has decreased by 3.8% and is now trading at $0.9619. View the best growth stocks for 2024 here. campaigner for short crossword

"WebFunding. Cingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate Therapeutics is registered under the ticker NASDAQ:CING . Their stock opened with $6.00 in its Dec 8, 2024 IPO. " - Cingulate therapeutics filing

Cingulate therapeutics filing

Cingulate Inc. Announces Pricing of $25.0 Million Initial Public …

WebSep 24, 2014 · Somerset, N.J. – September 24, 2014 — Catalent Pharma Solutions has reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics (CTx), to support the development of a series of new prescription pharmaceutical products for the treatment of Attention … WebMar 30, 2024 · (a) the Company’s latest annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended December 31, 2024, as filed with the Commission on ...

Did you know?

WebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the … WebCompany profile page for Cingulate Therapeutics LLC including stock price, company news, press releases, executives, board members, and contact information

WebJul 10, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both products in the first quarter of 2024 and will pursue approval via the accelerated 505 (b)(2) regulatory pathway. ... WebJul 11, 2024 · About Cingulate Therapeutics ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ...

WebCingulate Therapeutics is based out of Morristown. The firm last filed a Form D notice of exempt offering of securities on 2024-06-29. The notice included securities offered of …

WebFind the latest Cingulate Inc. (CING) stock quote, history, news and other vital information to help you with your stock trading and investing.

WebApr 6, 2024 · Alterity Therapeutics NASDAQ:ATHE; View All Competitors. Insiders & Institutions. HighTower Advisors LLC Bought 34,425 shares on 2/9/2024 Ownership: … campaigner enfp-t personalityWebCingulate Inc. Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation ... first signs of measlesWebDec 8, 2024 · Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to … first signs of male pubertyWebMar 10, 2024 · Inside Cingulate Inc.'s 10-K Annual Report: Financial - Expense Highlight. We have experienced, and will continue to experience, increased expenses associated … campaigner for shortWebUncategorized (1) Contracts. Master Services Agreement between Cingulate Therapeutics LLC and Societal CDMO, Inc., dated October 24, 2024 (Filed With SEC on October 25, 2024) Promissory Note, dated August 9, 2024, between Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC (Filed With SEC on August 11, 2024) … first signs of lymphedemaWebMay 31, 2024 · Cingulate anticipates filing INDs for CTX-1301 and CTX-1302 via the accelerated 505 (b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information ... campaigner email marketing reviewsWebShane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions at Pfizer ... first signs of male pattern baldness